Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirabegron versus solifenacin in overactive bladder after inadequate antimuscarinic response
2011-005713-37Phase 3Completed
- Sponsor
- Astellas Pharma
- Start
- Feb 2012
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in overactive bladder (OAB) comparing Mirabegron 50 mg with Solifenacin 5 mg (2 arms). Primary endpoint: Change from baseline in mean number of micturitions per 24 hours. Started Feb 2012; status: completed.
02
Drugs
mirabegronsolifenacin
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on 2011-005713-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005713-37.